Melanoma Molecular Maps Projects



Title: Hypoxia inducible factor 1 (HIF-1)
Legend: Hypoxia inducible factor 1 (HIF1) is the master regulator of cell response to hypoxic condition. It is a heterodimer composed of HIF1alpha (induced by hypoxia) and HIF1beta (constitutively expressed; also known as aryl hydrocarbon receptor nuclear translocator, ARNT). Under normoxia, HIF1alpha hydroxylation leads to its binding to VHL, which leads to its ubiquitination and degradation. HIF1 activity is often upregulated in tumors (including melanoma [5]), where it promotes aggressiveness (e.g. by enhancing angiogenesis). REFERENCES: [1] Semenza GL, Sci STKE 2007, 9:cm8. [2] Melillo G, Cancer Metastasis Rev 2007, 26:341-52. [3] Semenza GL, Drug Discov Today 2007, 12:853-9. [4] Liao D et al, Cancer Metastasis Rev 2007, 26:281-90. [5] Kumar SM et al, Cancer Res 2007, 67:3177-84. MOLECULES: ABCB1 (ATP binding cassette family B member 1), ABCG2 (ATP binding cassette family G member 2), Akt (protein kinase B, PKB), ARD1 (arrest defective protein 1, N-acetyltransferase), BAD, BRAF (MAP3K), BRCA1 (breast cancer 1), c-MET (hepatocyte growth factor [HGF] receptor), CREBBP (cAMP responsive element binding protein [CREB] binding protein, CBP), CUL2 (cullin 2), CXCL12 (chemokine C-X-C motif ligand 12), CXCR4 (chemokine C-X-C motif receptor 4), Delta (Delta-1, -3, -4: Notch ligands), E2F3 (transcription factor), EIF4E (eukaryotic translation initiation factor 4E), 4E-BP1 (EIF4E binding protein 1), Elongin-C (ELOC), EPO (erythropoietin), Ephrin A3, ERK (mitogen activated protein kinase, MAPK), ET1 (endothelin 1), FIH1 (factor inhibiting HIF1), gamma-secretase, GLUT1 (glucose transporter 1), GPCR (G protein coupled receptor), HATp300 (histone acetyltransferase p300), HDAC1 (histone deacetylase 1), HES (hairy/enhancer of split), HEY (HES related with YRPW motif), HSP90 (heat shock protein 90), hTERT (human telomerase), IAP (inhibitor of apoptosis), ID2 (inhibitor of DNA binding 2), IGF2 (insulin like growth factor 2), iNOS (inducible nitric oxide synthase, NOS2), Jagged (Jagged-1, -2: Notch ligands), MEK (MAP2K), microRNA (mir-210, mir-213, mir-103), MLH1 (mutL homolog 1), MNK (MAPK interacting kinase 1), MSH2 (mutS homolog 2), mTOR (mammalian target of rapamycin), NEC (Notch extracellular domain), NIC (Notch intracellular domain), NOTCH (Notch-1 to -4 receptors), Nucleophosmin, OCT4 (Octamer-binding transcription factor 4), p53, PDHK1 (Pyruvate dehydrogenase kinase 1), PDK1 (3-phosphoinositide dependent kinase 1), PGK1 (phosphoglycerate kinase 1), PHD2 (prolyl hydroxylase 2),PI3K (phosphatidylinositol 3 kinase), PIP2 (PI bisphosphate), PIP3 (PI trisphosphate), Proteasome, PTEN (phosphatase and tensin homolog), Rack1, RAD51, RAS, RBX1 (ring box 1; regulator of cullins 1, ROC1), REF1, RTK (receptor tyrosine kinase), S6K (ribosomal S6 kinase 1, RSK1), SRC1 (nuclear receptor coactivator 1, NCOA1), TACE (TNF alpha converting enzyme, ADAM17), TGFa (transforming growth factor alpha), uPAR (urokinase-type plasminogen activator), VEGF (vascular endothelial growth factor). Figure #59
Author: The MMMP Team (updated: March 2008)

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

NCBI's Disclaimer and Copyright notice